---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-013455"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:55:30.710175+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration

## Summary
- Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.
- Cash & investments $112.4M; sufficient into H1 2027; gross cash burn ~$72M in FY2024.
- ABS-101 anti-TL1A to enter Phase 1 in H1 2025; interim data expected H2 2025.
- AMD strategic collaboration includes $20M equity investment; AI drug discovery workloads.
- Expects to sign one or more drug creation partnerships in 2025, including with Large Pharma.

## SEC filing metadata
- accession: 0001628280-25-013455
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/0001628280-25-013455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/absc-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-013455
- JSON: https://secwatch.observer/filing/0001628280-25-013455.json
- Plain text: https://secwatch.observer/filing/0001628280-25-013455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.